Key features and details
- Rabbit polyclonal to DLL4
- Suitable for: IHC-P, WB
- Reacts with: Human
- Isotype: IgG
Product nameAnti-DLL4 antibody
See all DLL4 primary antibodies
DescriptionRabbit polyclonal to DLL4
Tested applicationsSuitable for: IHC-P, WBmore details
Species reactivityReacts with: Human
Recombinant fragment corresponding to Human DLL4 aa 168-345. (BC106950).
RYSYRVICSDNYYGDNCSRLCKKRNDHFGHYVCQPDGNLSCLPGWTGEYC QQPICLSGCHEQNGYCSKPAECLCRPGWQGRLCNECIPHNGCRHGTCSTP WQCTCDEGWGGLFCDQDLNYCTHHSPCKNGATCSNSGQRSYTCTCRPGYT GVDCELELSECDSNPCRNGGSCKDQEDG
Database link: Q9NR61
- Human fetal kidney and fetal lung lysates; Human fetal kidney tissue.
FormLyophilized:Reconstitute in 200 µl of steriled distilled water.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab176876 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||1/100 - 1/500.|
|WB||1/200 - 1/1000. Predicted molecular weight: 74 kDa.|
FunctionPlays a role in the Notch signaling pathway. Activates Notch-1 and Notch-4.
Tissue specificityExpressed in vascular endothelium.
Sequence similaritiesContains 1 DSL domain.
Contains 8 EGF-like domains.
DomainThe Delta-Serrate-Lag2 (DSL) domain is required for binding to the Notch receptor.
modificationsUbiquitinated by MIB (MIB1 or MIB2), leading to its endocytosis and subsequent degradation.
- Information by UniProt
- AOS6 antibody
- Delta 4 antibody
- delta 4 precursor antibody
ab176876 has been referenced in 2 publications.
- Verrienti A et al. RET mutation and increased angiogenesis in medullary thyroid carcinomas. Endocr Relat Cancer 23:665-76 (2016). PubMed: 27402614
- Yao Z & Sherif ZA The effect of epigenetic silencing and TP53 mutation on the expression of DLL4 in human cancer stem disorder. Oncotarget 7:62976-62988 (2016). PubMed: 27542210